Merck & Co., Inc. operates as a healthcare company ... Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under ...

Germany's Merck KGaA said on Tuesday its lab equipment division and its pharmaceuticals division would be under new ...

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

Deutsche Bank analyst James Shin downgraded Merck (MRK) to Hold from Buy with a price target of $105, down from $128. The firm believes the ...

Sitagliptin (Januvia™) is a new oral agent approved by the US FDA to treat Type 2 diabetes. This is the first approved agent in a new class of antihyperglycemics, dipeptidyl peptidase (DPP)-4 ...

Biopharmaceutical company Merck & Co., Inc. (MRK) reported Tuesday a net profit for the fourth quarter compared to a loss last year, ...

Merck on Tuesday issued full-year 2025 revenue ... cut HIV infections by 96% in trial Merck's Type 2 diabetes treatment, Januvia, also saw sales fall to $487 million during the quarter, down ...

Revenue from the diabetes drug Januvia fell 38% to $487 million, pressured by declining U.S. pricing. Merck's full-year 2025 forecast fell short of expectations. The company expects annual revenue ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.